Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.

Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, Hilsenbeck SG, Huang S, Rimawi MF, Gray JW, Osborne CK, Schiff R.

Mol Cancer Res. 2019 Aug 16. doi: 10.1158/1541-7786.MCR-19-0756. [Epub ahead of print]

PMID:
31420371
2.

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.

Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, Chamness GC, Jeselsohn R, Osborne CK, Schiff R.

Br J Cancer. 2019 Feb;120(3):331-339. doi: 10.1038/s41416-018-0354-9. Epub 2018 Dec 17.

PMID:
30555156
3.

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.

Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R.

Clin Cancer Res. 2017 Sep 1;23(17):5123-5134. doi: 10.1158/1078-0432.CCR-16-2191. Epub 2017 May 9.

4.

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.

Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R.

Clin Cancer Res. 2015 Sep 1;21(17):3995-4003. doi: 10.1158/1078-0432.CCR-14-2728. Epub 2015 May 26.

5.

Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells.

Suo J, Medina D, Herrera S, Zheng ZY, Jin L, Chamness GC, Contreras A, Gutierrez C, Hilsenbeck S, Umar A, Foekens JA, Hanash S, Schiff R, Zhang XH, Chang EC.

Cell Biosci. 2015 Mar 8;5:10. doi: 10.1186/s13578-015-0001-6. eCollection 2015.

6.

Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.

Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJ, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XS.

Nat Commun. 2014 Aug 7;5:4577. doi: 10.1038/ncomms5577.

7.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28.

8.

Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer.

Bu W, Chen J, Morrison GD, Huang S, Creighton CJ, Huang J, Chamness GC, Hilsenbeck SG, Roop DR, Leavitt AD, Li Y.

Oncogene. 2011 Oct 27;30(43):4399-409. doi: 10.1038/onc.2011.147. Epub 2011 May 2.

9.

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.

J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.

10.

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.

Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC.

J Clin Oncol. 2011 Jan 10;29(2):166-73. doi: 10.1200/JCO.2009.27.7814. Epub 2010 Dec 6.

11.

DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.

Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC.

Breast Cancer Res Treat. 2010 Aug;123(1):189-96. doi: 10.1007/s10549-010-0983-z. Epub 2010 Jun 26.

PMID:
20582464
12.

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.

Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM.

Cancer. 2010 Mar 1;116(5):1234-42. doi: 10.1002/cncr.24816.

13.

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.

De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Andò S, Fuqua SA.

Breast Cancer Res Treat. 2010 May;121(1):1-11. doi: 10.1007/s10549-009-0436-8. Epub 2009 Jun 17.

14.

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC.

J Natl Cancer Inst. 2008 May 7;100(9):672-9. doi: 10.1093/jnci/djn123. Epub 2008 Apr 29.

PMID:
18445819
15.

Molecular profiles of progesterone receptor loss in human breast tumors.

Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R.

Breast Cancer Res Treat. 2009 Mar;114(2):287-99. doi: 10.1007/s10549-008-0017-2. Epub 2008 Apr 19.

16.

Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients.

Chang JC, Makris A, Gutierrez MC, Hilsenbeck SG, Hackett JR, Jeong J, Liu ML, Baker J, Clark-Langone K, Baehner FL, Sexton K, Mohsin S, Gray T, Alvarez L, Chamness GC, Osborne CK, Shak S.

Breast Cancer Res Treat. 2008 Mar;108(2):233-40. Epub 2007 Apr 28.

PMID:
17468949
17.

Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.

Tham YL, Gomez LF, Mohsin S, Gutierrez MC, Weiss H, Hilsenbeck SG, Elledge RM, Chamness GC, Osborne CK, Allred DC, Chang JC.

Breast Cancer Res Treat. 2005 Dec;94(3):279-84.

PMID:
16261403
18.

Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations.

Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, Cowin P, Schiff R, Li Y.

Oncogene. 2005 Jun 16;24(26):4220-31.

PMID:
15824740
19.

Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P.

J Clin Oncol. 2005 Feb 20;23(6):1169-77.

PMID:
15718313
20.

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC.

J Clin Oncol. 2005 Apr 10;23(11):2460-8. Epub 2005 Feb 14.

PMID:
15710948
21.
22.

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P.

Lancet. 2003 Aug 2;362(9381):362-9.

PMID:
12907009
23.

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R.

J Natl Cancer Inst. 2003 Mar 5;95(5):353-61.

PMID:
12618500
24.

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.

Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK.

J Natl Cancer Inst. 2000 Dec 6;92(23):1926-34.

PMID:
11106684
25.

Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients.

Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC, Elledge RM.

J Clin Oncol. 2000 May;18(9):1906-13.

PMID:
10784631
26.

Time-dependence of hazard ratios for prognostic factors in primary breast cancer.

Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM.

Breast Cancer Res Treat. 1998;52(1-3):227-37.

PMID:
10066085
27.

Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.

Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH.

Cancer Res. 1997 Dec 15;57(24):5505-8.

28.

The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients.

Oesterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, Fuqua SA.

Clin Cancer Res. 1996 Jul;2(7):1199-206.

30.

Rising levels of estrogen receptor in breast cancer over 2 decades.

Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM.

Cancer. 1994 Sep 1;74(5):1601-6.

PMID:
8062191
31.

Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.

Elledge RM, Clark GM, Chamness GC, Osborne CK.

J Natl Cancer Inst. 1994 May 4;86(9):705-12.

PMID:
7908990
32.

Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer.

Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SA, Hilsenbeck SH, Chamness GC, Osborne CK.

J Clin Oncol. 1994 Mar;12(3):467-74.

PMID:
8120545
33.

Constitutive overexpression of the 27,000 dalton heat shock protein in late passage human breast cancer cells.

Fuqua SA, Benedix MG, Krieg S, Weng CN, Chamness GC, Oesterreich S.

Breast Cancer Res Treat. 1994;32(2):177-86.

PMID:
7865847
34.

Translational research in the San Antonio breast cancer SPORE.

Osborne CK, Chamness GC.

Breast Cancer Res Treat. 1994;32(1):1-4. No abstract available.

PMID:
7819578
35.

Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review.

Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA.

J Natl Cancer Inst. 1993 Oct 6;85(19):1558-70. Review.

PMID:
8411230
36.

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.

Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL.

J Natl Cancer Inst. 1993 Feb 3;85(3):200-6.

PMID:
8423624
37.

Estrogen receptor mutations in breast cancer.

Fuqua SA, Chamness GC, McGuire WL.

J Cell Biochem. 1993 Feb;51(2):135-9. Review.

PMID:
8440747
38.

Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques.

Molina R, Ciocca DR, Tandon AK, Allred DC, Clark GM, Chamness GC, Gullick WJ, McGuire WL.

Anticancer Res. 1992 Nov-Dec;12(6B):1965-71.

PMID:
1363511
39.

Prognosis and treatment decisions in patients with breast cancer without axillary node involvement.

McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM.

Cancer. 1992 Sep 15;70(6 Suppl):1775-81.

PMID:
1355403
40.

Abnormal estrogen receptor in clinical breast cancer.

McGuire WL, Chamness GC, Fuqua SA.

J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):243-7. Review.

PMID:
1525064
41.

Treatment decisions in axillary node-negative breast cancer patients.

McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM.

J Natl Cancer Inst Monogr. 1992;(11):173-80.

PMID:
1627425
42.

Abnormal oestrogen receptor in clinical breast cancer.

McGuire WL, Chamness GC, Fuqua SA.

Eur J Cancer. 1992;28(2-3):309-10. Review. No abstract available.

PMID:
1591044
43.

The importance of normal and abnormal oestrogen receptor in breast cancer.

McGuire WL, Chamness GC, Fuqua SA.

Cancer Surv. 1992;14:31-40. Review.

PMID:
1423328
44.

Estrogen receptor variants in clinical breast cancer.

McGuire WL, Chamness GC, Fuqua SA.

Mol Endocrinol. 1991 Nov;5(11):1571-7. Review.

PMID:
1779964
45.

Progesterone receptor gene restriction fragment length polymorphisms in human breast tumors.

Fuqua SA, Hill SM, Chamness GC, Benedix MG, Greene GL, O'Malley BW, McGuire WL.

J Natl Cancer Inst. 1991 Aug 21;83(16):1157-60.

PMID:
1679459
46.

17 alpha-substituted analogs of estradiol for the development of fluorescent estrogen receptor ligands.

Salman M, Reddy BR, Delgado P, Stotter PL, Fulcher LC, Chamness GC.

Steroids. 1991 Jul;56(7):375-87.

PMID:
1780954
47.
48.

Variant human breast tumor estrogen receptor with constitutive transcriptional activity.

Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O'Malley BW, McGuire WL.

Cancer Res. 1991 Jan 1;51(1):105-9.

49.

Estrogen receptor gene methylation in human breast tumors.

Falette NS, Fuqua SA, Chamness GC, Cheah MS, Greene GL, McGuire WL.

Cancer Res. 1990 Jul 1;50(13):3974-8.

50.

How to use prognostic factors in axillary node-negative breast cancer patients.

McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM.

J Natl Cancer Inst. 1990 Jun 20;82(12):1006-15. Review. No abstract available.

PMID:
2189998

Supplemental Content

Loading ...
Support Center